Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
632 A phase 1/2 open label study of LabVax 3(22)-23 and adjuvant GM-CSF alone or in combination with pembrolizumab in subjects with labyrinthin-positive adenocarcinomas
Compose a Response to This Article
Other responses
No responses have been published for this article.
